GP-Leds

The secondaries market anticipates 2024 will be a record year for volume, with first-half figures coming in at between $68bn and $72bn.

There's a growing set of more than 28,000 buyout companies with diminished IPO and M&A exit avenues, according to Kline Hill Partners' Mike Bego.

The $1.2bn secondaries transaction involves R1 RCM, a healthcare sector revenue cycle management services provider.

The firm has temporarily delayed capital raising for GP Equity Solutions and is instead focusing on dealmaking, Secondaries Investor has learned.

The deal marks the first continuation vehicle for Guardian Capital Partners.

While continuation funds are increasingly common liquidity solutions, not all of them are delivering the appropriate returns, according to Cari Lodge, head of secondaries at Commonfund.

The fund will be managed by Ant Solutions Partners, a newly formed spinoff of Ant Capital’s Solution Investment Group.

The firm was a participating investor in a single-asset CV for Essential Pharma.

Coller Capital's latest barometer has found that most investors see the main purpose of continuation funds as providing an alternative to selling assets at a low valuation.

The private markets firm backed a GP-led process involving Spain’s Bluesea, a hospitality platform.